

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Lorcaserin hydrochloride for the treatment of obesity and overweight

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Arena Pharmaceuticals (lorcaserin hydrochloride) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Beat • Black and Ethnic Minority Diabetes Association • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • Counsel and Care • Diabetes Research & Wellness Foundation • Diabetes UK • Equalities National Council • Healthier Weight Centres • Heart Care Partnership UK • HEART UK • Insulin Dependent Diabetes Trust • Muslim Council of Great Britain • Muslim Health Network • National Obesity Forum • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance • Surya Foundation • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • British Association for Nursing in Cardiac Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Services • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (orlistat) • Roche Products (orlistat) • Vivus (phentermine with topiramate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiovascular Diseases Specialist Library • Cochrane Heart Group • Cochrane Metabolic & Endocrine Disorders Group

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight

Issue date: October 2012

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Services to the Elderly • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Nutrition Foundation • Diabetes Specialist Nurses • Dieticians in Obesity Management • Faculty of Public Health Medicine • National Centre for Eating Disorders • National Diabetes Nurse Consultant Group • National Heart Forum UK • Primary Care Cardiovascular Society • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society for Vascular Nurses • The Nutrition Society • The Obesity Management Association • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Staffordshire PCT Cluster • Sussex PCT cluster • Welsh Assembly Government 	<ul style="list-style-type: none"> • Cochrane Peripheral Vascular Disease Group • Cochrane Public Health Group • CODA • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People • Wellcome Trust <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • Southampton Health Technology Assessment Centre <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.